Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.
The hearing giant is still mulling over the independent listing of Hear.com.
The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.
The unpredictable world situation in the spring of 2020 meant that the timing of product launches was frequently discussed at Demant-owned Oticon, located in Denmark.
With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.
That millions of people have not been able to get their hearing aids adjusted due to the pandemic has caused a huge backlog, and according to Demant CEO Søren Nielsen, this will impact the industry for some time.
The preclinical collaboration with the US cancer hospital MD Anderson could prove crucial for the biotech company when it raises capital in 2022.
In December last year, Sonova dished out almost EUR 5m to Sensorion, a French biotech company specialized in the treatment of hearing disorders. Now, the two companies are entering into a strategic partnership with the goal of improving diagnostics and treatment through genetic analysis.
HERA, the new EU health authority inspired by the US counterpart BARDA, is tasked with anticipating and preparing for future health emergencies.
The Lancet has published new data on Johnson & Johnson and Bavarian Nordic's combined vaccine against Ebola, which according to the US life science group strongly supports preventatitve use of the vaccine.
A lack of short-term catalysts is one of the reasons that investment bank Jefferies has changed its recommendation for Genmab stock. The biotech company's share price increase since the start of the year is another reason, as S&P's biotech index has fallen during the same period.
The Danish Lundbeck Foundation acquires 25 percent of asset manager Cresco Capital Services, which has climate among its focal areas and invests in energy projects.
Leo Pharma partner Pellepharm's drug patidegib has not generated sufficiently convincing phase III data for the dermatology group to utilize its acquisition option and take over the candidate – and the company.
While Novo Nordisk struggles to meet the demand for its injection-based treatment Wegovy in the US, the pharmaceutical company has started a phase IIIa trial of semaglutide as a tablet-based treatment for obesity, aiming for similar weight loss results.
Despite previous statements against a vaccine mandate for its US workforce, the medtech company is now enforcing that very same requirement, writes business daily Børsen.
A Danish scientist is set to lead the new genomics research center in the US, which the Novo Nordisk Foundation is establishing in collaboration with the Broad Institute of MIT and Harvard.
The Covid-19 variant is not disrupting the company's sales on the US market.
Hearing aid manufacturer WS Audiology has invested in the sustainable conversion of its Singapore headquarters and facility. The company, which is the third-biggest in the industry, is now well on its way towards the goal of running on 100 percent renewable energy by 2025.
IO Biotech joins forces with partner MSD in the development of a new therapy for the treatment of skin cancer in combination with IO Biotech's lead candidate Keytruda. A big phase III trial now commences, and if successful, IO Biotech maintains commercial rights.
In the second half of next year, Amplifon expects to see the first over-the-counter products on the US market.
The first patient has now received a dose of Galecto's drug candidate GB1211 in a crucial phase 1b/2a trial meant to assess its efficacy in treating liver cirrhosis.
According to the media network Euractiv, the European Commission will be discussing a proposed future body to organise the union's health emergency preparedness, known as HERA.
On Sep. 8, Olympus was hit by a possible data breach, which the medtech company managed to avert without any operational disruptions.
A potential launch of Y-mabs's drug Danyelza is one step closer after being granted priority review status, ensuring a faster assessment by the Chinese authorities.
An "impressive" launch of Novo Nordisk's new obesity treatment Wegovy has led US investment group Jefferies to increase its expectations for the Danish pharmaceutical company.
Scientific Advisor infectious disease - Vaccibody 
Human Resources Senior Business Partner - Orifarm 
Senior Downstream Scientist - Symphogen 
Clinical Research Specialist, Post Market Clinical Development - Ambu Senior QA Specialist - Vaccibody 
Medical Scientific Liaison Dermo aesthetic, IBSA 
Associate Director, PV QA - Y-mAbs Therapeutics 
CMC Senior Project Manager - Genmab Senior Project Leader - Vaccibody 
Senior Drug Product Specialist - Zealand Pharma 
Project Manager, Adcendo ApS Analysis Chemist for Quality Control in Orifarm Manufacturing Viminco Formulation Development Specialist – Product Lifecycle Management (PLM), Orifarm Senior Clinical Research Specialist - Ambu Scientist, Adcendo ApS Development Laboratory Manager - Pharmaceutical Product Development - Orifarm 
Global Senior Medical Advisor – Neurology Pipeline Projects, Lundbeck Analytical Coordinator - Symphogen Medical Director (diabetes and obesity) - Zealand Pharma Analytical Specialist – Product Lifecycle Management (PLM), Orifarm 
Director of Communications – Evaxion Biotech 
Employee of the regulatory department with knowledge of food safety and legislation within dietary supplements and medicines 
KLIFO is looking for an experienced and skilled Proposal Manager for one of our offices in Denmark, Sweden or Germany Senior Manager, QA GMP - Genmab QA Specialist wanted 
